Tumor neutrophil extracellular traps and pretreatment neutrophils in association with progression-free survival in patients with metastatic non-small cell lung cancer receiving pembrolizumab alone or with chemotherapy.
Rattachement africain : bg. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
e21099 Background: Background: In this multicentric retrospective study, we evaluated the relationship between pre- treatment blood neutrophils and neutrophil extracellular traps (NET) in biopsy samples and their predictive value for progression progression-free survival (PFS) in patients with non-small-cell lung cancer (NSCLC) receiving immunotherapy alone or in combination with chemotherapy as a first-line treatment. Methods: Patients with metastatic NSCLC (n = 100) were retrospectively analyzed between Apr 2018 and Sep 2021; 77.5% of the patients received platinum-containing chemotherapy with Pembrolizumab, and 22.5% – Pembrolizumab only as a first-line treatment. Pre-treatment blood neutrophils were counted. Tissue sections were stained immunohistochemically for Neutrophil elastase (NE) and Histone H3. Both NE and Histone H3 stained tissue areas were calculated manually and determined by Image-J software. We considered the extracellular components that were double-positive for NE and H3 to be NET. Results: In correspondence analysis, patients with low levels (< 33rd percentile) of pre-treatment neutrophils were grouped with low amounts (< 33rd percentile) of NET-positive tumor areas (p = 0.02). The amounts of NET-positive tumor areas were not related to other clinicopathological characteristics of the patients. Patients with an intermediate/high amount of NET-positive areas had significantly shorter mean PFS, 10.7 (95% CI: 9.6–11.8) than those with low NET-positive areas, 14.8 (95% CI: 11.5–18.1) (log-rank test p = 0.003). Moreover, in a multivariate Cox regression model, the presence of an intermediate/high amount of NET-positive areas was an independent predictive factor for shorter PFS, HR 2.1 (95% CI: 1.2–3.7; p = 0.005). Conclusions: Our study suggests that tumor formation of NETs is related to the numbers of pre-treatment neutrophils and may mediate neutrophil-induced antitumor resistance. Excessive NET formation in tumor tissue is a potential negative predictive marker for shorter PFS.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Tumor neutrophil extracellular traps and pretreatment neutrophils in association with progression-free survival in patients with metastatic non-small cell lung cancer receiving pembrolizumab alone or with chemotherapy.
- Date Crossref
- 01/06/2022
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University Specialized Hospital for Active Treatment of Endocrinology pays non établi dans la noticeÉtablissement de santé
-
MHAT “Nadezhda” pays non établi dans la noticeInstitution
-
MHAT Nadezhda Hospital Research Department pays non établi dans la noticeÉtablissement de santé
-
Clinical Pathology Laboratory pays non établi dans la noticeStructure de recherche
-
University Specialized Oncology Hospital Department of General and Clinical Pathology pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Laboratory pays non établi dans la noticeStructure de recherche
-
Medical Oncology Dept pays non établi dans la noticeInstitution
-
MHAT for Womens Health - Nadezhda pays non établi dans la noticeInstitution
-
MHAT UniHospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
MHAT Uni Hospital Panagiurishte Department of Radiotherapy pays non établi dans la noticeÉtablissement de santé
University Specialized Hospital for Active Treatment of Endocrinology, MHAT “Nadezhda” et Research Department — MHAT Nadezhda Hospital, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.